NICE recommendations for GLP-1 therapy include: For type 2 diabetes (NICE NG28): GLP-1 therapy should only be continued if there is a beneficial metabolic response (HbA1c reduction of 11 mmol/mol [1.0%] and weight loss of 3% of initial body weight at 6 months)
The Centers for Medicare and Medicaid Services and the National Center for Health Statistics provide guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)
The impact of probiotics on gut microbiota in the eradication of Helicobacter pylori infection: a systematic review
So far, BPC-157 has shown a low risk for toxicity and adverse reactions, even at higher doses, in multiple preclinical trials
Epitalon is notable among bioregulatory peptides for the breadth of its published preclinical literature, including studies in cell culture, animal models, and limited human observational studies conducted in Russia